Mobile website
Clinical Research
Effects of anti-PD-1 antibody immunotherapy on prognosis of patients with nonsmall cell lung cancer and cachexia
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the effects of anti-programmed death 1 (PD-1) immunotherapy on the prognosis of patients with non-small cell lung cancer (NSCLC) complicated with cachexia. Methods: A total of 80 patients with cachexia associated with NSCLC, treated at Xijing Hospital between January 2019 and January 2021, were enrolled in this study. These patients were divided into two groups using a random number table: a control group and an observation group. The control group was given sequential chemoradiotherapy and other symptomatic treatments, as well as nutritional therapy. The observation group was treated with combined anti-PD-1 antibody immunotherapy. Clinical efficacy and improvement in physical condition were compared between the two groups. Pulmonary function and immune function in patients were observed before and after treatment. The patients were followed up for one year after treatment, and their cumulative 1-year survival rate was calculated. Results: There were no significant differences in disease control rate (DCR) and objective response rate (ORR) between the two groups of NSCLC patients (all P > 0.05). However, compared with the control group, the observation group showed significantly higher appetite score, Karnofsky performance status (KPS) score, and higher proportions of CD3+ and CD4+ /CD8+ lymphocyte subsets (all P < 0.05); additionally, the forced expiratory volume in 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FEV1/FVC) in the observation group were also higher than those in control group (all P < 0.05). At the 1-year follow-up, the survival rate in observation group was significantly higher than that in the control group (62.50% vs 40.00%, P < 0.05). Conclusion: Anti-PD-1 antibody immunotherapy can alleviate immune dysfunction and pulmonary function impairment in NSCLC patients with cachexia, and it significantly improves the 1-year survival rate of these patients.
Keywords:
Project Supported:
Clc Number:
